Aurora Cannabis acquires Safari Flower to boost exports to Europe

Aurora Cannabis announced in mid-April the acquisition of Safari Flower Company, an operation aimed at consolidating its position in medical cannabis and increasing its supply of certified flowers EU-GMP for export.

The transaction, unveiled on April 15, 2026, is valued at $26.5 million, subject to customary adjustments. The agreement calls for a cash payment of $15 million at closing, and the issuance of 2,417,180 Aurora common shares to the seller. An additional cash payment of $2 million remains subject to the satisfaction of certain conditions.

An operation to capitalize on the international boom in medical cannabis

Safari Flower Company operates a 2-hectare indoor growing and manufacturing facility in Ontario, Canada. The facility is described as purpose-built, and is already EU GMP certified, This is a key requirement for exporting cannabis products to many regulated European markets, particularly Germany.

According to Aurora, this additional production capacity will be integrated into its existing network of cultivation and manufacturing sites. The company hopes that this site will help strengthen its supply chain and support increased exports of EU GMP flowers.

Miguel Martin, Aurora's Executive Chairman and CEO, emphasized that this transaction is part of the company's long-term strategy to establish a strong international presence.

«The acquisition of Safari Flower Company marks an important milestone for Aurora, as we continue to make targeted investments in the expansion of our EU GMP-compliant production to support the growing international medical cannabis market.»

Mr. Martin added that Aurora intends to use its plant science expertise and operational know-how to increase production and strengthen its presence abroad.

«We intend to leverage our extensive plant science and operations expertise to increase the supply of high-quality flowers manufactured to EU GMP standards, further strengthening our leadership in these growing, high-margin, highly regulated markets.»

Strengthening supply in Germany, Australia, Poland and the UK

Aurora said the new capacity will be used to supply cannabis flowers to several key markets where demand continues to grow, including the’Germany, theAustralia, Poland and the United Kingdom, all of which have seen significant growth in patient access to medical cannabis in recent years.

Germany, in particular, remains one of the most strategic destinations for GMP-certified products from the EU, with rising imports and high prices compared to the Canadian domestic market. Poland and the UK have also established themselves as growing medical markets, while Australia remains one of the most active non-European importers.

Aurora also indicated that this acquisition could support further expansion beyond these key markets, depending on regulatory developments and patient demand.

With GMP-certified production sites in Canada and in Germany, Aurora is positioned as one of the leading international suppliers capable of meeting stringent pharmaceutical quality requirements, even more so than before. since it left the recreational market.